» Articles » PMID: 31387945

A Strategy for the Selection of Monovalent Antibodies That Span Protein Dimer Interfaces

Overview
Journal J Biol Chem
Specialty Biochemistry
Date 2019 Aug 8
PMID 31387945
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

Ligand-induced dimerization is the predominant mechanism through which secreted proteins activate cell surface receptors to transmit essential biological signals. Cytokines are a large class of soluble proteins that dimerize transmembrane receptors into precise signaling topologies, but there is a need for alternative, engineerable ligand scaffolds that specifically recognize and stabilize these protein interactions. Recombinant antibodies can potentially serve as robust and versatile platforms for cytokine complex stabilization, and their specificity allows for tunable modulation of dimerization equilibrium. Here, we devised an evolutionary strategy to isolate monovalent antibody fragments that bridge together two different receptor subunits in a cytokine-receptor complex, precisely as the receptors are disposed in their natural signaling orientations. To do this, we screened a naive antibody library against a stabilized ligand-receptor ternary complex that acted as a "molecular cast" of the natural receptor dimer conformation. Our selections elicited "stapler" single-chain variable fragments (scFvs) of antibodies that specifically engage the interleukin-4 receptor heterodimer. The 3.1 Å resolution crystal structure of one such stapler revealed that, as intended, this scFv recognizes a composite epitope between the two receptors as they are positioned in the complex. Extending our approach, we evolved a stapler scFv that specifically binds to and stabilizes the interface between the interleukin-2 cytokine and one of its receptor subunits, leading to a 15-fold enhancement in interaction affinity. This demonstration that scFvs can be selected to recognize epitopes that span protein interfaces presents new opportunities to engineer structurally defined antibodies for a broad range of research and therapeutic applications.

Citing Articles

An engineered palivizumab IgG2 subclass for synthetic gp130 and fas-mediated signaling.

Wittich C, Ettich J, Hertell M, Roy B, Ghosh Roy B, Xu H J Biol Chem. 2025; 301(3):108205.

PMID: 39828098 PMC: 11872477. DOI: 10.1016/j.jbc.2025.108205.


Directed-evolution approach to empower EGFR targeting for immunotherapy.

Meksiriporn B, Spangler J Cell Rep Methods. 2024; 4(4):100762.

PMID: 38631347 PMC: 11046029. DOI: 10.1016/j.crmeth.2024.100762.


Molecular Engineering of Interleukin-2 for Enhanced Therapeutic Activity in Autoimmune Diseases.

Tomasovic L, Liu K, VanDyke D, Fabilane C, Spangler J BioDrugs. 2023; 38(2):227-248.

PMID: 37999893 PMC: 10947368. DOI: 10.1007/s40259-023-00635-0.


Structural insights into the assembly and activation of the IL-27 signaling complex.

Jin Y, Fyfe P, Gardner S, Wilmes S, Bubeck D, Moraga I EMBO Rep. 2022; 23(10):e55450.

PMID: 35920255 PMC: 9535766. DOI: 10.15252/embr.202255450.


A comprehensive comparison between camelid nanobodies and single chain variable fragments.

Asaadi Y, Jouneghani F, Janani S, Rahbarizadeh F Biomark Res. 2021; 9(1):87.

PMID: 34863296 PMC: 8642758. DOI: 10.1186/s40364-021-00332-6.


References
1.
Hage T, Sebald W, Reinemer P . Crystal structure of the interleukin-4/receptor alpha chain complex reveals a mosaic binding interface. Cell. 1999; 97(2):271-81. DOI: 10.1016/s0092-8674(00)80736-9. View

2.
Muller-Newen G, Kuster A, Wijdenes J, Schaper F, Heinrich P . Studies on the interleukin-6-type cytokine signal transducer gp130 reveal a novel mechanism of receptor activation by monoclonal antibodies. J Biol Chem. 2000; 275(7):4579-86. DOI: 10.1074/jbc.275.7.4579. View

3.
Shanafelt A, Lin Y, Shanafelt M, Forte C, Carter C, Gibbons J . A T-cell-selective interleukin 2 mutein exhibits potent antitumor activity and is well tolerated in vivo. Nat Biotechnol. 2000; 18(11):1197-202. DOI: 10.1038/81199. View

4.
Constantinescu S, Keren T, Socolovsky M, Nam H, Henis Y, Lodish H . Ligand-independent oligomerization of cell-surface erythropoietin receptor is mediated by the transmembrane domain. Proc Natl Acad Sci U S A. 2001; 98(8):4379-84. PMC: 31843. DOI: 10.1073/pnas.081069198. View

5.
Levy D, Darnell Jr J . Stats: transcriptional control and biological impact. Nat Rev Mol Cell Biol. 2002; 3(9):651-62. DOI: 10.1038/nrm909. View